Onconova Therapeutics Stock Price, News & Analysis (NASDAQ:ONTX)

$1.07 +0.01 (+0.94 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$1.07
Today's Range$1.05 - $1.07
52-Week Range$0.95 - $3.88
Volume75,656 shs
Average Volume337,539 shs
Market Capitalization$20.78 million
P/E Ratio-0.39
Dividend YieldN/A
Beta0.08

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.97%
Quick Ratio0.97%

Price-To-Earnings

Trailing P/E Ratio-0.386281588447653
Forward P/E Ratio-0.38
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.55 million
Price / Sales3.74
Cash FlowN/A
Price / CashN/A
Book Value$0.76 per share
Price / Book1.41

Profitability

Trailing EPS($2.77)
Net Income$-19,660,000.00
Net Margins-2,855.94%
Return on Equity-558.97%
Return on Assets-144.30%

Miscellaneous

Employees23
Outstanding Shares19,420,000

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) announced its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.02. The biopharmaceutical company earned $0.11 million during the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. View Onconova Therapeutics' Earnings History.

When will Onconova Therapeutics make its next earnings announcement?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Onconova Therapeutics.

Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2018?

4 analysts have issued 1-year price objectives for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Onconova Therapeutics' stock price to reach $7.33 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:

  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (1/10/2018)
  • 2. HC Wainwright analysts commented, "Rigosertib Expanding Footprint; Moving Forward With CRADA to Address RASopathies Moving forward on RASopathies with NCI. Onconova announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of rigosertib in pediatric cancer associated RASopathies. The NCI is to conduct and fund the majority of research, including preclinical laboratory studies and a clinical trial, whereas Onconova is expected to provide rigosertib and initial funding for non-clinical studies. The studies are slated to start in 2018. The NCI is to focus on RASopathy related cancers in pediatric patients, whereas Onconova is expecting to focus on Juvenile Myelomonocytic Leukemia (JMML). This event signifies the potential expansion of rigosertib use in a number of cancers and syndromes driven by RAS pathway hyperactivation." (1/4/2018)
  • 3. Maxim Group analysts commented, "Onconova reported 3Q17 with a net loss of $7M and ended the period with $7.6M in cash. We forecast that Onconova will need to raise capital. The question then is, at what valuation and how much? The next catalyst for the company is the interim analysis of the INSPIRE pivotal phase 3 trial in Myelodysplastic Syndrome, which is expected in 4Q17. The interim analysis is dependent on reaching 88 events (deaths). Several scenarios could play out which we have profiled in prior notes and below. Conclusion: Good data will drive this company and set the stage to raise additional capital." (11/9/2017)

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:

  • Michael M. B Hoffman, Chairman of the Board (Age 66)
  • Ramesh Kumar Ph.D., President, Chief Executive Officer, Director (Age 59)
  • Mark Guerin, Chief Financial Officer (Age 47)
  • Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer (Age 64)
  • Manoj Maniar Ph.D., Senior Vice President - Product Development (Age 52)
  • Henry S. Bienen Ph.D., Director (Age 76)
  • Jerome E. Groopman M.D., Director (Age 63)
  • Viren Mehta Ph.D., Director (Age 65)
  • E. Premkumar Reddy Ph.D., Director (Age 71)
  • Jack E. Stover CPA, Director (Age 64)

Who owns Onconova Therapeutics stock?

Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (5.21%) and 683 Capital Management LLC (4.32%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Who sold Onconova Therapeutics stock? Who is selling Onconova Therapeutics stock?

Onconova Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Onconova Therapeutics.

Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?

Onconova Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy Onconova Therapeutics stock?

Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of Onconova Therapeutics stock can currently be purchased for approximately $1.07.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $20.78 million and generates $5.55 million in revenue each year. The biopharmaceutical company earns $-19,660,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. Onconova Therapeutics employs 23 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (ONTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Onconova Therapeutics (NASDAQ:ONTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.753.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.33$7.33$7.33$8.00
Price Target Upside: 326.36% upside326.36% upside283.94% upside318.85% upside

Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History

Price Target History for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018HC WainwrightReiterated RatingBuy$6.00HighView Rating Details
1/17/2018Maxim GroupDowngradeBuy -> HoldHighView Rating Details
7/25/2017Dawson JamesReiterated RatingBuyHighView Rating Details
4/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00LowView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Onconova Therapeutics (NASDAQ:ONTX) Earnings History and Estimates Chart

Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ ONTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018($0.70)N/AView Earnings Details
11/9/2017Q3 2017($0.73)($0.71)$0.29 million$0.11 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.72)($0.29)$0.25 million$0.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.96)($1.23)$0.21 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.54)$0.17 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/11/2016Q1($0.19)($0.27)$1.34 million$1.47 millionViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18$9.60 millionViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)$0.11 million$1.62 millionViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)$0.11 million$0.12 millionViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)$0.11 million$0.11 millionViewN/AView Earnings Details
3/26/2015($0.71)($0.62)$0.11 millionViewN/AView Earnings Details
11/13/2014($0.78)($0.69)$0.11 millionViewN/AView Earnings Details
8/13/2014($0.89)($0.77)$0.56 million$0.13 millionViewN/AView Earnings Details
5/12/2014($0.78)($0.87)$1.32 million$0.45 millionViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Onconova Therapeutics (NASDAQ:ONTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.82 EPS
Next Year EPS Consensus Estimate: $-1.87 EPS

Dividends

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 25.45%
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ ONTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018683 Capital Management, LlcMajor ShareholderBuy200,000$1.04$208,000.00View SEC Filing  
4/26/2017E Premkumar ReddyDirectorBuy119,048$2.10$250,000.80385,832View SEC Filing  
4/26/2017Mark Patrick GuerinCFOBuy1,429$2.10$3,000.905,155View SEC Filing  
4/26/2017Ramesh KumarInsiderBuy23,810$2.10$50,001.00View SEC Filing  
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.604,518,275View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.001,278,718View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.004,307,500View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.0014,935View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Onconova Therapeutics (NASDAQ ONTX) News Headlines

Source:
DateHeadline
Onconova Therapeutics Announces Closing of $10 Million ... - GlobeNewswire (press release)Onconova Therapeutics Announces Closing of $10 Million ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:00 AM
Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional SecuritiesOnconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Securities
finance.yahoo.com - February 13 at 6:00 AM
683 Capital Management, Llc Buys 200,000 Shares of Onconova Therapeutics Inc (ONTX) Stock683 Capital Management, Llc Buys 200,000 Shares of Onconova Therapeutics Inc (ONTX) Stock
www.americanbankingnews.com - February 12 at 6:46 PM
 Brokerages Anticipate Onconova Therapeutics Inc (ONTX) Will Post Earnings of -$0.71 Per Share Brokerages Anticipate Onconova Therapeutics Inc (ONTX) Will Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 12 at 11:30 AM
Reviewing Syndax Pharmaceuticals (SNDX) and Onconova Therapeutics (ONTX)Reviewing Syndax Pharmaceuticals (SNDX) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - February 10 at 9:28 AM
Onconova Therapeutics Announces Pricing of $8.7 Million ... - GlobeNewswire (press release)Onconova Therapeutics Announces Pricing of $8.7 Million ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:19 PM
Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at ... - GlobeNewswire (press release)Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at ... - GlobeNewswire (press release)
globenewswire.com - February 3 at 5:50 AM
Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research ConferenceOnconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research Conference
finance.yahoo.com - February 2 at 3:20 PM
Onconova Therapeutics Inc (ONTX) Receives Consensus Rating of "Hold" from AnalystsOnconova Therapeutics Inc (ONTX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 31 at 1:34 AM
$310,000.00 in Sales Expected for Onconova Therapeutics Inc (ONTX) This Quarter$310,000.00 in Sales Expected for Onconova Therapeutics Inc (ONTX) This Quarter
www.americanbankingnews.com - January 28 at 4:42 AM
Opiant Pharmaceuticals (OPNT) and Onconova Therapeutics (ONTX) Head to Head ComparisonOpiant Pharmaceuticals (OPNT) and Onconova Therapeutics (ONTX) Head to Head Comparison
www.americanbankingnews.com - January 25 at 1:06 AM
Onconova Therapeutics (ONTX) "Buy" Rating Reiterated at HC WainwrightOnconova Therapeutics' (ONTX) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 18 at 7:00 PM
38 Stocks Moving In Wednesdays Mid-Day Session - Benzinga38 Stocks Moving In Wednesday's Mid-Day Session - Benzinga
www.benzinga.com - January 18 at 4:14 PM
Maxim Group Lowers Onconova Therapeutics (ONTX) to HoldMaxim Group Lowers Onconova Therapeutics (ONTX) to Hold
www.americanbankingnews.com - January 17 at 3:12 PM
Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim AnalysisOnconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis
finance.yahoo.com - January 17 at 10:06 AM
Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing TrialOnconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial
finance.yahoo.com - January 12 at 4:34 PM
Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $410,000.00Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $410,000.00
www.americanbankingnews.com - January 11 at 8:20 AM
Onconova Therapeutics (ONTX) Upgraded to "Hold" at Zacks Investment ResearchOnconova Therapeutics (ONTX) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 10 at 6:00 AM
Zacks: Analysts Anticipate Onconova Therapeutics Inc (ONTX) to Post -$0.72 EPSZacks: Analysts Anticipate Onconova Therapeutics Inc (ONTX) to Post -$0.72 EPS
www.americanbankingnews.com - January 9 at 11:36 AM
Onconova Therapeutics (ONTX) Reports Cooperative Research and Development Agreement with the National Cancer Institute for RigosertiOnconova Therapeutics (ONTX) Reports Cooperative Research and Development Agreement with the National Cancer Institute for Rigoserti
www.streetinsider.com - January 4 at 4:44 PM
Onconova Therapeutics (ONTX) Given a $6.00 Price Target at HC WainwrightOnconova Therapeutics (ONTX) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - January 4 at 12:40 PM
Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the ... - GlobeNewswire (press release)Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the ... - GlobeNewswire (press release)
globenewswire.com - January 4 at 10:07 AM
Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer InstituteOnconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute
finance.yahoo.com - January 4 at 10:07 AM
Onconova Therapeutics to Present at Biotech Showcase in January - GlobeNewswire (press release)Onconova Therapeutics to Present at Biotech Showcase in January - GlobeNewswire (press release)
globenewswire.com - December 30 at 9:57 AM
Onconova Therapeutics to Present at Biotech Showcase in JanuaryOnconova Therapeutics to Present at Biotech Showcase in January
finance.yahoo.com - December 28 at 4:43 PM
Comparing Optimer Pharmaceuticals (OPTR) & Onconova Therapeutics (ONTX)Comparing Optimer Pharmaceuticals (OPTR) & Onconova Therapeutics (ONTX)
www.americanbankingnews.com - December 26 at 4:08 PM
Onconova Therapeutics (ONTX) Downgraded to Sell at Zacks Investment ResearchOnconova Therapeutics (ONTX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - December 25 at 9:26 AM
Onconova Therapeutics Inc (ONTX) Expected to Announce Earnings of -$0.72 Per ShareOnconova Therapeutics Inc (ONTX) Expected to Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - December 24 at 1:08 AM
Wired News – Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300Wired News – Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300
finance.yahoo.com - December 21 at 10:13 AM
Onconova Therapeutics (ONTX) PT Set at $6.00 by HC WainwrightOnconova Therapeutics (ONTX) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - December 19 at 11:10 AM
Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5
finance.yahoo.com - December 19 at 10:15 AM
Financial Survey: Ambit Biosciences (AMBI) and Onconova Therapeutics (ONTX)Financial Survey: Ambit Biosciences (AMBI) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - December 15 at 9:14 AM
Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 MeetingOnconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting
finance.yahoo.com - December 12 at 10:39 AM
Onconova Therapeutics Inc (ONTX) Given Average Rating of "Hold" by AnalystsOnconova Therapeutics Inc (ONTX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 12 at 3:46 AM
Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?
finance.yahoo.com - December 9 at 10:12 AM
 Brokerages Expect Onconova Therapeutics Inc (ONTX) Will Post Quarterly Sales of $410,000.00 Brokerages Expect Onconova Therapeutics Inc (ONTX) Will Post Quarterly Sales of $410,000.00
www.americanbankingnews.com - December 8 at 12:58 PM
-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter
www.americanbankingnews.com - December 6 at 7:52 AM
 Onconova Therapeutics Inc (ONTX) Given $5.67 Average Target Price by Analysts Onconova Therapeutics Inc (ONTX) Given $5.67 Average Target Price by Analysts
www.americanbankingnews.com - December 4 at 8:54 AM
Does Onconova Therapeutics Inc’s (ONTX) Past Performance Indicate A Weaker Future?Does Onconova Therapeutics Inc’s (ONTX) Past Performance Indicate A Weaker Future?
finance.yahoo.com - November 30 at 4:40 PM
Onconova Therapeutics to Present at the LD Micro Conference in December - GlobeNewswire (press release)Onconova Therapeutics to Present at the LD Micro Conference in December - GlobeNewswire (press release)
globenewswire.com - November 21 at 9:03 AM
Onconova Therapeutics to Present at the LD Micro Conference in DecemberOnconova Therapeutics to Present at the LD Micro Conference in December
finance.yahoo.com - November 21 at 9:03 AM
$410,000.00 in Sales Expected for Onconova Therapeutics, Inc. (ONTX) This Quarter$410,000.00 in Sales Expected for Onconova Therapeutics, Inc. (ONTX) This Quarter
www.americanbankingnews.com - November 20 at 10:32 AM
Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid LeukemiaOnconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia
finance.yahoo.com - November 18 at 10:40 AM
Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual MeetingOnconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting
finance.yahoo.com - November 18 at 10:40 AM
Head to Head Review: Onconova Therapeutics (ONTX) & Alimera Sciences (ALIM)Head to Head Review: Onconova Therapeutics (ONTX) & Alimera Sciences (ALIM)
www.americanbankingnews.com - November 16 at 3:12 AM
Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 14 at 6:30 AM
Onconova Therapeutics (ONTX) CEO Ramesh Kumar on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaOnconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 8:33 AM
Onconova Therapeutics, Inc. (ONTX) Posts Quarterly  Earnings Results, Beats Expectations By $0.02 EPSOnconova Therapeutics, Inc. (ONTX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 10 at 11:10 PM
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 10 at 2:57 PM
Edited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMTEdited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMT
finance.yahoo.com - November 10 at 2:57 PM

SEC Filings

Onconova Therapeutics (NASDAQ:ONTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.